Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Radioligand Therapy Market

ID: MRFR/Pharma/50332-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026

Japan Radioligand Therapy RLT Market Research Report: Size, Share, Trend Analysis By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Radioligand Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. EXECUTIVE SUMMARY
    1. Market Overview
    2. Key Findings
    3. Market Segmentation
    4. Competitive Landscape
    5. Challenges and Opportunities
    6. Future Outlook
  2. MARKET INTRODUCTION
    1. Definition
    2. Scope of the study
    3. Research Objective
    4. Assumption
    5. Limitations
  3. RESEARCH METHODOLOGY
    1. Overview
    2. Data Mining
    3. Secondary Research
    4. Primary Research
    5. Primary Interviews and Information Gathering Process
    6. Breakdown of Primary Respondents
    7. Forecasting Model
    8. Market Size Estimation
    9. Bottom-Up Approach
    10. Top-Down Approach
    11. Data Triangulation
    12. Validation
  4. MARKET DYNAMICS
    1. Overview
    2. Drivers
    3. Restraints
    4. Opportunities
  5. MARKET FACTOR ANALYSIS
    1. Value chain Analysis
    2. Porter's Five Forces Analysis
    3. Bargaining Power of Suppliers
    4. Bargaining Power of Buyers
    5. Threat of New Entrants
    6. Threat of Substitutes
    7. Intensity of Rivalry
    8. COVID-19 Impact Analysis
    9. Market Impact Analysis
    10. Regional Impact
    11. Opportunity and Threat Analysis
  6. Japan Radioligand Therapy Market, BY Isotope (USD Million)
    1. Fluorine – 18
    2. Gallium – 68
    3. Lutetium – 177
    4. Others
  7. Japan Radioligand Therapy Market, BY Targeted Receptor (USD Million)
    1. Prostate-specific Membrane Antigen (PSMA)
    2. Somatostatin Receptor (SSTR)
    3. Epidermal Growth Factor Receptor (EGFR)
    4. Others
  8. Japan Radioligand Therapy Market, BY Indication (USD Million)
    1. Prostate Cancer
    2. Neuroendocrine Tumors (NETs)
    3. Breast Cancer
    4. Others
  9. Japan Radioligand Therapy Market, BY End User (USD Million)
    1. Hospitals & Clinics
    2. Diagnostic Centers
    3. Others
    4. Competitive Landscape
    5. Overview
    6. Competitive Analysis
    7. Market share Analysis
    8. Major Growth Strategy in the Radioligand Therapy RLT Market
    9. Competitive Benchmarking
    10. Leading Players in Terms of Number of Developments in the Radioligand Therapy RLT Market
    11. Key developments and growth strategies
    12. New Product Launch/Service Deployment
    13. Merger & Acquisitions
    14. Joint Ventures
    15. Major Players Financial Matrix
    16. Sales and Operating Income
    17. Major Players R&D Expenditure. 2023
    18. Company Profiles
    19. Lantheus Medical Imaging
    20. Financial Overview
    21. Products Offered
    22. Key Developments
    23. SWOT Analysis
    24. Key Strategies
    25. Eisai
    26. Financial Overview
    27. Products Offered
    28. Key Developments
    29. SWOT Analysis
    30. Key Strategies
    31. Novartis
    32. Financial Overview
    33. Products Offered
    34. Key Developments
    35. SWOT Analysis
    36. Key Strategies
    37. Endocyte
    38. Financial Overview
    39. Products Offered
    40. Key Developments
    41. SWOT Analysis
    42. Key Strategies
    43. Amgen
    44. Financial Overview
    45. Products Offered
    46. Key Developments
    47. SWOT Analysis
    48. Key Strategies
    49. Siemens Healthineers
    50. Financial Overview
    51. Products Offered
    52. Key Developments
    53. SWOT Analysis
    54. Key Strategies
    55. Cardinal Health
    56. Financial Overview
    57. Products Offered
    58. Key Developments
    59. SWOT Analysis
    60. Key Strategies
    61. GE Healthcare
    62. Financial Overview
    63. Products Offered
    64. Key Developments
    65. SWOT Analysis
    66. Key Strategies
    67. Telix Pharmaceuticals
    68. Financial Overview
    69. Products Offered
    70. Key Developments
    71. SWOT Analysis
    72. Key Strategies
    73. Zymeworks
    74. Financial Overview
    75. Products Offered
    76. Key Developments
    77. SWOT Analysis
    78. Key Strategies
    79. Bayer
    80. Financial Overview
    81. Products Offered
    82. Key Developments
    83. SWOT Analysis
    84. Key Strategies
    85. YmAbs Therapeutics
    86. Financial Overview
    87. Products Offered
    88. Key Developments
    89. SWOT Analysis
    90. Key Strategies
    91. Biontech
    92. Financial Overview
    93. Products Offered
    94. Key Developments
    95. SWOT Analysis
    96. Key Strategies
    97. Advanced Accelerator Applications
    98. Financial Overview
    99. Products Offered
    100. Key Developments
    101. SWOT Analysis
    102. Key Strategies
    103. Akron Biotech
    104. Financial Overview
    105. Products Offered
    106. Key Developments
    107. SWOT Analysis
    108. Key Strategies
    109. Appendix
    110. References
    111. Related Reports
    112. LIST Of tables
  10. LIST OF ASSUMPTIONS
  11. Japan Radioligand Therapy RLT Market SIZE ESTIMATES & Japan Radioligand Therapy Market, BY ISOTOPE, 2019-2035 (USD Billions)
  12. Japan Radioligand Therapy RLT Market SIZE ESTIMATES & Japan Radioligand Therapy Market, BY TARGETED RECEPTOR, 2019-2035 (USD Billions)
  13. Japan Radioligand Therapy RLT Market SIZE ESTIMATES & Japan Radioligand Therapy Market, BY INDICATION, 2019-2035 (USD Billions)
  14. Japan Radioligand Therapy RLT Market SIZE ESTIMATES & Japan Radioligand Therapy Market, BY END USER, 2019-2035 (USD Billions)
    1. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    2. ACQUISITION/PARTNERSHIP
    3. LIST Of figures
  15. MARKET SYNOPSIS
    1. JAPAN RADIOLIGAND THERAPY RLT MARKET ANALYSIS BY ISOTOPE
    2. JAPAN RADIOLIGAND THERAPY RLT MARKET ANALYSIS BY TARGETED RECEPTOR
    3. JAPAN RADIOLIGAND THERAPY RLT MARKET ANALYSIS BY INDICATION
    4. JAPAN RADIOLIGAND THERAPY RLT MARKET ANALYSIS BY END USER
  16. KEY BUYING CRITERIA OF RADIOLIGAND THERAPY RLT MARKET
    1. RESEARCH PROCESS OF MRFR
  17. DRO ANALYSIS OF RADIOLIGAND THERAPY RLT MARKET
    1. DRIVERS IMPACT ANALYSIS: RADIOLIGAND THERAPY RLT MARKET
    2. RESTRAINTS IMPACT ANALYSIS: RADIOLIGAND THERAPY RLT MARKET
    3. SUPPLY / VALUE CHAIN: RADIOLIGAND THERAPY RLT MARKET
  18. Japan Radioligand Therapy Market, BY ISOTOPE, 2025 (% SHARE)
  19. Japan Radioligand Therapy Market, BY ISOTOPE, 2019 TO 2035 (USD Billions)
  20. Japan Radioligand Therapy Market, BY TARGETED RECEPTOR, 2025 (% SHARE)
  21. Japan Radioligand Therapy Market, BY TARGETED RECEPTOR, 2019 TO 2035 (USD Billions)
  22. Japan Radioligand Therapy Market, BY INDICATION, 2025 (% SHARE)
  23. Japan Radioligand Therapy Market, BY INDICATION, 2019 TO 2035 (USD Billions)
  24. Japan Radioligand Therapy Market, BY END USER, 2025 (% SHARE)
  25. Japan Radioligand Therapy Market, BY END USER, 2019 TO 2035 (USD Billions)
    1. BENCHMARKING OF MAJOR COMPETITORS

Japan Radioligand Therapy Market Segmentation

 

 

 

  • Japan Radioligand Therapy Market By Isotope (USD Million, 2019-2035)

    • Fluorine – 18
    • Gallium – 68
    • Lutetium – 177
    • Others

 

  • Japan Radioligand Therapy Market By Targeted Receptor (USD Million, 2019-2035)

    • Prostate-specific Membrane Antigen (PSMA)
    • Somatostatin Receptor (SSTR)
    • Epidermal Growth Factor Receptor (EGFR)
    • Others

 

  • Japan Radioligand Therapy Market By Indication (USD Million, 2019-2035)

    • Prostate Cancer
    • Neuroendocrine Tumors (NETs)
    • Breast Cancer
    • Others

 

  • Japan Radioligand Therapy Market By End User (USD Million, 2019-2035)

    • Hospitals & Clinics
    • Diagnostic Centers
    • Others

 

 

 

 

 

 

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓